Exploring Apremilast and Axial Psoriatic Arthritis

This chapter reviews recent studies on the safety and efficacy of apremilast in treating axial psoriatic arthritis, emphasizing the need for further research in this area. It discusses the significant improvements noted in patients over a 48-week period and the contrasting effects of different treatment options. The discussion also highlights apremilast's potential metabolic advantages, particularly in younger patients, and calls for ongoing studies to better assess its clinical utility.